An ECOG trial has recently opened for patients that undergo salvage resection of recurrent or second primary HNSCC that have high-risk features of ENE and/or positive margins and PD-L1 CPS ≥1. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.